| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 2004;44:490.)
© 2004 American Heart Association, Inc.
Scientific Contributions |
From the Departamento de Fisiologia e Biofísica (S.V.B.P., W.O.S., R.D.D., E.P.M., E.D.B., R.A.S.S.), Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Brazil; Departamento de Pediatria (A.C.S.), Faculdade de Medicina, Universidade Federal de Minas Gerais, Brazil; Departamento de Biofísica da Universidade Federal de São Paulo, Brazil (J.B.P.); Department of Pharmacology (T.W.), Erasmus Medical Center, Rotterdam, Netherlands; Max-Delbrück Center for Molecular Medicine (N.A., M. Bader), Berlin, Germany; and Physiologisches Institut (M. Bleich), Christan-Albrechts-University of Kiel, Germany.
Correspondence to Robson Augusto Souza dos Santos, MD, PhD, Department of Physiology and Biophysics, Institute of Biological Sciences Federal University of Minas Gerais, Avenida Antônio Carlos, 6627 Pampulha, Belo Horizonte 31270-901 Minas Gerais, Brazil. E-mail marrob{at}dedalus.lcc.ufmg.br
It has been described recently that the nonpeptide AVE 0991 (AVE) mimics the effects of angiotensin-(17) [Ang-(17)] in bovine endothelial cells. In this study, we tested the possibility that AVE is an agonist of the Ang-(17) receptor Mas, in vitro and in vivo. In water-loaded C57BL/6 mice, AVE (0.58 nmol/g body weight) produced a significant reduction in urinary volume (0.06±0.03 mL/60 min [n=9] versus 0.27±0.05 [n=9]; P<0.01), associated with an increase in urinary osmolality. The Ang-(17) antagonist A-779 completely blocked the antidiuretic effect of AVE. As observed previously for Ang-(17), the antidiuretic effect of AVE after water load was blunted in Mas-knockout mice (0.37±0.10 mL/60 min [n=9] versus 0.27±0.03 mL/60 min [n=11] AVE-treated mice). In vitro receptor autoradiography in C57BL/6 mice showed that the specific binding of 125I-Ang-(17) to mouse kidney slices was displaced by AVE, whereas no effects were observed in the binding of 125I-angiotensin II or 125I-angiotensin IV. Furthermore, AVE displaced the binding of 125I-Ang-(17) in Mas-transfected monkey kidney cells (COS) cells (IC50=4.75x108 mol/L) and of rhodamineAng-(17) in Mas-transfected Chinese hamster ovary (CHO) cells. It also produced NO release in Mas-transfected CHO cells blocked by A-779 but not by angiotensin II type-1 (AT1) and AT2 antagonists. Contrasting with these data, the antidiuretic effect of AVE was totally blocked by AT2 antagonists and partially blocked (
60%) by AT1 antagonists. The binding data, the results obtained in Mas-knockout mice and in Mas-transfected cells, show that AVE is a Mas receptor agonist. Our data also suggest the involvement of AT2/AT1-related mechanisms, including functional antagonism, oligomerization or cross-talk, in the renal responses to AVE.
Key Words: receptors, angiotensin angiotensin angiotensin II
This article has been cited by other articles:
![]() |
N. Alenina, P. Xu, B. Rentzsch, E. L. Patkin, and M. Bader Genetically altered animal models for Mas and angiotensin-(1-7) Exp Physiol, May 1, 2008; 93(5): 528 - 537. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. S. Santos, A. J. Ferreira, and A. C. Simoes e Silva Recent advances in the angiotensin-converting enzyme 2-angiotensin(1-7)-Mas axis Exp Physiol, May 1, 2008; 93(5): 519 - 527. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. H. Zucker Angiotensin-Converting Enzyme 2: A New Player in Central Sympathetic Regulation? Circ. Res., March 28, 2008; 102(6): 628 - 629. [Full Text] [PDF] |
||||
![]() |
M. B.L. Carvalho, F. V. Duarte, R. Faria-Silva, B. Fauler, L. T. da Mata Machado, R. D. de Paula, M. J. Campagnole-Santos, and R. A.S. Santos Evidence for Mas-Mediated Bradykinin Potentiation by the Angiotensin-(1-7) Nonpeptide Mimic AVE 0991 in Normotensive Rats Hypertension, October 1, 2007; 50(4): 762 - 767. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. K. Becker, G. M. Etelvino, T. Walther, R. A. S. Santos, and M. J. Campagnole-Santos Immunofluorescence localization of the receptor Mas in cardiovascular-related areas of the rat brain Am J Physiol Heart Circ Physiol, September 1, 2007; 293(3): H1416 - H1424. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Ianzer, R. A. S. Santos, G. M. Etelvino, C. H. Xavier, J. de Almeida Santos, E. P. Mendes, L. T. Machado, B. C. Prezoto, V. Dive, and A. C. M. de Camargo Do the Cardiovascular Effects of Angiotensin-Converting Enzyme (ACE) I Involve ACE-Independent Mechanisms? New Insights from Proline-Rich Peptides of Bothrops jararaca J. Pharmacol. Exp. Ther., August 1, 2007; 322(2): 795 - 805. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Toda, K. Ayajiki, and T. Okamura Interaction of Endothelial Nitric Oxide and Angiotensin in the Circulation Pharmacol. Rev., March 1, 2007; 59(1): 54 - 87. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Keidar, M. Kaplan, and A. Gamliel-Lazarovich ACE2 of the heart: From angiotensin I to angiotensin (1-7) Cardiovasc Res, February 1, 2007; 73(3): 463 - 469. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. F. Benter, M. H. M. Yousif, C. Cojocel, M. Al-Maghrebi, and D. I. Diz Angiotensin-(1-7) prevents diabetes-induced cardiovascular dysfunction Am J Physiol Heart Circ Physiol, January 1, 2007; 292(1): H666 - H672. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A.S. Santos, C. H. Castro, E. Gava, S. V.B. Pinheiro, A. P. Almeida, R. D. de Paula, J. S. Cruz, A. S. Ramos, K. T. Rosa, M. C. Irigoyen, et al. Impairment of In Vitro and In Vivo Heart Function in Angiotensin-(1-7) Receptor Mas Knockout Mice Hypertension, May 1, 2006; 47(5): 996 - 1002. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Fleming Signaling by the Angiotensin-Converting Enzyme Circ. Res., April 14, 2006; 98(7): 887 - 896. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. F. Benter, M. H. M. Yousif, J. T. Anim, C. Cojocel, and D. I. Diz Angiotensin-(1-7) prevents development of severe hypertension and end-organ damage in spontaneously hypertensive rats treated with L-NAME Am J Physiol Heart Circ Physiol, February 1, 2006; 290(2): H684 - H691. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Iwata, R. T. Cowling, D. Gurantz, C. Moore, S. Zhang, J. X.-J. Yuan, and B. H. Greenberg Angiotensin-(1-7) binds to specific receptors on cardiac fibroblasts to initiate antifibrotic and antitrophic effects Am J Physiol Heart Circ Physiol, December 1, 2005; 289(6): H2356 - H2363. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Faria-Silva, F. V. Duarte, and R. A.S. Santos Short-Term Angiotensin(1-7) Receptor Mas Stimulation Improves Endothelial Function in Normotensive Rats Hypertension, October 1, 2005; 46(4): 948 - 952. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. H. de Castro, R. A. Souza dos Santos, A. J. Ferreira, M. Bader, N. Alenina, and A. Pinto de Almeida Evidence for a Functional Interaction of the Angiotensin-(1-7) Receptor Mas With AT1 and AT2 Receptors in the Mouse Heart Hypertension, October 1, 2005; 46(4): 937 - 942. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Q. Gomes da Silva, R. A. Sousa dos Santos, and M. A. Peliky Fontes Blockade of Endogenous Angiotensin-(1-7) in the Hypothalamic Paraventricular Nucleus Reduces Renal Sympathetic Tone Hypertension, August 1, 2005; 46(2): 341 - 348. [Abstract] [Full Text] [PDF] |
||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2004 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |